deCODE Chemistry and FSMA Announce Extension of Research Agreement
News Jan 17, 2006
Initiated in 2003, the deCODE chemistry-FSMA collaboration focused on optimization of a class of molecule that was discovered in a high-throughput, cell-based phenotypic assay developed under sponsorship by FSMA.
The focus of the collaboration in the coming year will be to further assess the pharmaceutical properties of lead candidates and select a small number of analogues for IND-directed, pre-clinical development.
"We are pleased to continue our collaboration with FSMA on this important program," said Dr. David Zembower, Vice President of Chemistry at deCODE chemistry.
"We are encouraged by the progress that has been made over the past year, and look forward to working with FSMA to help them achieve their goals."
"There has been much progress in SMA research since our relationship with deCODE began, and we are proud that our collaborative effort has been a part of that," said Dr. Jill Jarecki, FSMA Research Director.
"We are confident that our pioneering endeavor has the potential to enable a novel treatment for SMA."
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Molecule Prevents Common Cold Virus from Hijacking Human CellsNews
Researchers have lab-tested a molecule that can combat the common cold virus by preventing it from hijacking human cells.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018